Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;9(3):632-634.
doi: 10.1002/iid3.450. Epub 2021 May 12.

COVID-19 infection in CVID patients: What we know so far

Niels Weifenbach  1   2 , Alisha Jung  1 , Stefan Lötters  1
Affiliations

COVID-19 infection in CVID patients: What we know so far

Niels Weifenbach et al. Immun Inflamm Dis. 2021 Sep.

Abstract

Introduction: In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID-19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID-19 poses to CVID patients and the best-known treatments.

Method: Review of 14 publications.

Results: The number of CVID patients with moderate to severe (~29%) and critical infection courses (~10%), and the number of fatal cases (~13%), are increased compared to the general picture of COVID-19 infection. However, this might be an overestimate. Systematic cohort-wide studies are lacking, and asymptomatic or mild cases among CVID patients occur that can easily remain unnoticed. Regular immunoglobulin replacement therapy was administered in almost all patients, potentially explaining why the numbers of critical and fatal cases were not higher. In addition, the application of convalescent plasma was demonstrated to have positive effects.

Conclusions: COVID-19 poses an elevated threat to CVID patients. However, only systematic studies can provide robust information on the extent of this threat. Regular immunoglobulin replacement therapy is beneficial to combat COVID-19 in CVID patients, and best treatment after infection includes the use of convalescent plasma in addition to common medication.

Keywords: SARS-CoV-2; common variable immunodeficiency; convalescent plasma; immunoglobulin replacement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

References

    1. Yong PFK, Thaventhiran JED, Grimbacher B. A rose is a rose is a rose, but CVID is not CVID: common variable immune deficiency (CVID), what do we know in 2011? Advanc Immunol. 2011;111:47‐107. 10.1016/B978-0-12-385991-4.00002-7 - DOI - PubMed
    1. Gathmann B, Mahlaoui N, Ceredih L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116‐126. 10.1016/j.jaci.2013.12.1077 - DOI - PubMed
    1. Aljaberi A, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2020;125:349‐350. 10.1016/j.anai.2020.06.006 - DOI - PMC - PubMed
    1. Petricau C, Nedelea I, Deleanu D. Surprising protective mechanisms against severe forms of COVID‐19 infection among common variable immunodeficiency patients—one center experience [published online ahead of print March 2, 2021]. Research Square. 10.21203/rs.3.rs-57542/v1 - DOI
    1. Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147:520‐531. 10.1016/j.jaci.2020.09.010 - DOI - PMC - PubMed